These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16134723)

  • 1. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides.
    Braun J; Baraliakos X; Brandt J; Sieper J
    Scand J Rheumatol; 2005; 34(3):178-90. PubMed ID: 16134723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.
    Braun J; van der Heijde D
    Expert Opin Investig Drugs; 2003 Jul; 12(7):1097-109. PubMed ID: 12831346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
    Braun J; Brandt J; Listing J; Rudwaleit M; Sieper J
    Curr Opin Rheumatol; 2003 Jul; 15(4):394-407. PubMed ID: 12819466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy for ankylosing spondylitis: new treatment modalities.
    Braun J; Breban M; Maksymowych WP
    Best Pract Res Clin Rheumatol; 2002 Sep; 16(4):631-51. PubMed ID: 12406431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
    Braun J; Sieper J
    Arthritis Res; 2002; 4(5):307-21. PubMed ID: 12223105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis].
    Langer HE
    Wien Med Wochenschr; 2008; 158(7-8):200-5. PubMed ID: 18500471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF-alpha therapy with infliximab in spondyloarthritides.
    Baraliakos X; Braun J
    Expert Rev Clin Immunol; 2010 Jan; 6(1):9-19. PubMed ID: 20383886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis.
    Braun J; Kalden JR
    Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S164-7. PubMed ID: 19822066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current concepts in the therapy of the spondyloarthritides.
    Baraliakos X; Braun J
    BioDrugs; 2004; 18(5):307-14. PubMed ID: 15377173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ankylosing spondylitis--the current situation and new therapeutic options].
    Zlnay D; Zlnay M; Rovenský J
    Vnitr Lek; 2006; 52(7-8):730-5. PubMed ID: 16967616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.
    Braun J; de Keyser F; Brandt J; Mielants H; Sieper J; Veys E
    Curr Opin Rheumatol; 2001 Jul; 13(4):245-9. PubMed ID: 11555723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists].
    Brandt J; Sieper J; Braun J
    Z Rheumatol; 2003 Jun; 62(3):218-27. PubMed ID: 12827397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.
    De Keyser F; Baeten D; Van den Bosch F; Kruithof E; Verbruggen G; Mielants H; Veys E
    Drugs; 2004; 64(24):2793-811. PubMed ID: 15563249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spondyloarthritides.
    Baraliakos X; Braun J
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):825-42. PubMed ID: 22265264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.
    Sieper J; Braun J
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii58-61. PubMed ID: 11890656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.